Report cover image

Global Human Erythropoietin Market Analysis and Forecast 2025-2031

Publisher APO Research, Inc.
Published May 17, 2025
Length 194 Pages
SKU # APRC20361707

Description

Summary

According to APO Research, The global Human Erythropoietin market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Human Erythropoietin is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Human Erythropoietin is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Human Erythropoietin is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Human Erythropoietin is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Human Erythropoietin include 3SBio, Biocon, Emcure, Galenica, Kyowa Hakko Kirin, LG Life Sciences, Amgen, Roche and Johnson & Johnson, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Human Erythropoietin, market size. Analyses of the global market trends, with historic market revenue data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Human Erythropoietin, also provides the revenue of main regions and countries. Of the upcoming market potential for Human Erythropoietin, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Human Erythropoietin revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Human Erythropoietin market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for Human Erythropoietin revenue, projected growth trends, production technology, application and end-user industry.

Human Erythropoietin Segment by Company

3SBio
Biocon
Emcure
Galenica
Kyowa Hakko Kirin
LG Life Sciences
Amgen
Roche
Johnson & Johnson
Human Erythropoietin Segment by Type

Darbepoetin-alfa
Epoetin-alfa
Epoetin-beta
Others
Human Erythropoietin Segment by Application

Anemia
Kidney Disorders
Others
Human Erythropoietin Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Erythropoietin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Human Erythropoietin and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Erythropoietin.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Human Erythropoietin in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Human Erythropoietin company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Human Erythropoietin revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.

Table of Contents

194 Pages
1 Market Overview
1.1 Product Definition
1.2 Human Erythropoietin Market by Type
1.2.1 Global Human Erythropoietin Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Darbepoetin-alfa
1.2.3 Epoetin-alfa
1.2.4 Epoetin-beta
1.2.5 Others
1.3 Human Erythropoietin Market by Application
1.3.1 Global Human Erythropoietin Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Anemia
1.3.3 Kidney Disorders
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Human Erythropoietin Market Dynamics
2.1 Human Erythropoietin Industry Trends
2.2 Human Erythropoietin Industry Drivers
2.3 Human Erythropoietin Industry Opportunities and Challenges
2.4 Human Erythropoietin Industry Restraints
3 Global Growth Perspective
3.1 Global Human Erythropoietin Market Perspective (2020-2031)
3.2 Global Human Erythropoietin Growth Trends by Region
3.2.1 Global Human Erythropoietin Market Size by Region: 2020 VS 2024 VS 2031
3.2.2 Global Human Erythropoietin Market Size by Region (2020-2025)
3.2.3 Global Human Erythropoietin Market Size by Region (2026-2031)
4 Competitive Landscape by Players
4.1 Global Human Erythropoietin Revenue by Players
4.1.1 Global Human Erythropoietin Revenue by Players (2020-2025)
4.1.2 Global Human Erythropoietin Revenue Market Share by Players (2020-2025)
4.1.3 Global Human Erythropoietin Players Revenue Share Top 10 and Top 5 in 2024
4.2 Global Human Erythropoietin Key Players Ranking, 2023 VS 2024 VS 2025
4.3 Global Human Erythropoietin Key Players Headquarters & Area Served
4.4 Global Human Erythropoietin Players, Product Type & Application
4.5 Global Human Erythropoietin Players Establishment Date
4.6 Market Competitive Analysis
4.6.1 Global Human Erythropoietin Market CR5 and HHI
4.6.3 2024 Human Erythropoietin Tier 1, Tier 2, and Tier 3
5 Human Erythropoietin Market Size by Type
5.1 Global Human Erythropoietin Revenue by Type (2020 VS 2024 VS 2031)
5.2 Global Human Erythropoietin Revenue by Type (2020-2031)
5.3 Global Human Erythropoietin Revenue Market Share by Type (2020-2031)
6 Human Erythropoietin Market Size by Application
6.1 Global Human Erythropoietin Revenue by Application (2020 VS 2024 VS 2031)
6.2 Global Human Erythropoietin Revenue by Application (2020-2031)
6.3 Global Human Erythropoietin Revenue Market Share by Application (2020-2031)
7 Company Profiles
7.1 3SBio
7.1.1 3SBio Comapny Information
7.1.2 3SBio Business Overview
7.1.3 3SBio Human Erythropoietin Revenue and Gross Margin (2020-2025)
7.1.4 3SBio Human Erythropoietin Product Portfolio
7.1.5 3SBio Recent Developments
7.2 Biocon
7.2.1 Biocon Comapny Information
7.2.2 Biocon Business Overview
7.2.3 Biocon Human Erythropoietin Revenue and Gross Margin (2020-2025)
7.2.4 Biocon Human Erythropoietin Product Portfolio
7.2.5 Biocon Recent Developments
7.3 Emcure
7.3.1 Emcure Comapny Information
7.3.2 Emcure Business Overview
7.3.3 Emcure Human Erythropoietin Revenue and Gross Margin (2020-2025)
7.3.4 Emcure Human Erythropoietin Product Portfolio
7.3.5 Emcure Recent Developments
7.4 Galenica
7.4.1 Galenica Comapny Information
7.4.2 Galenica Business Overview
7.4.3 Galenica Human Erythropoietin Revenue and Gross Margin (2020-2025)
7.4.4 Galenica Human Erythropoietin Product Portfolio
7.4.5 Galenica Recent Developments
7.5 Kyowa Hakko Kirin
7.5.1 Kyowa Hakko Kirin Comapny Information
7.5.2 Kyowa Hakko Kirin Business Overview
7.5.3 Kyowa Hakko Kirin Human Erythropoietin Revenue and Gross Margin (2020-2025)
7.5.4 Kyowa Hakko Kirin Human Erythropoietin Product Portfolio
7.5.5 Kyowa Hakko Kirin Recent Developments
7.6 LG Life Sciences
7.6.1 LG Life Sciences Comapny Information
7.6.2 LG Life Sciences Business Overview
7.6.3 LG Life Sciences Human Erythropoietin Revenue and Gross Margin (2020-2025)
7.6.4 LG Life Sciences Human Erythropoietin Product Portfolio
7.6.5 LG Life Sciences Recent Developments
7.7 Amgen
7.7.1 Amgen Comapny Information
7.7.2 Amgen Business Overview
7.7.3 Amgen Human Erythropoietin Revenue and Gross Margin (2020-2025)
7.7.4 Amgen Human Erythropoietin Product Portfolio
7.7.5 Amgen Recent Developments
7.8 Roche
7.8.1 Roche Comapny Information
7.8.2 Roche Business Overview
7.8.3 Roche Human Erythropoietin Revenue and Gross Margin (2020-2025)
7.8.4 Roche Human Erythropoietin Product Portfolio
7.8.5 Roche Recent Developments
7.9 Johnson & Johnson
7.9.1 Johnson & Johnson Comapny Information
7.9.2 Johnson & Johnson Business Overview
7.9.3 Johnson & Johnson Human Erythropoietin Revenue and Gross Margin (2020-2025)
7.9.4 Johnson & Johnson Human Erythropoietin Product Portfolio
7.9.5 Johnson & Johnson Recent Developments
8 North America
8.1 North America Human Erythropoietin Revenue (2020-2031)
8.2 North America Human Erythropoietin Revenue by Type (2020-2031)
8.2.1 North America Human Erythropoietin Revenue by Type (2020-2025)
8.2.2 North America Human Erythropoietin Revenue by Type (2026-2031)
8.3 North America Human Erythropoietin Revenue Share by Type (2020-2031)
8.4 North America Human Erythropoietin Revenue by Application (2020-2031)
8.4.1 North America Human Erythropoietin Revenue by Application (2020-2025)
8.4.2 North America Human Erythropoietin Revenue by Application (2026-2031)
8.5 North America Human Erythropoietin Revenue Share by Application (2020-2031)
8.6 North America Human Erythropoietin Revenue by Country
8.6.1 North America Human Erythropoietin Revenue by Country (2020 VS 2024 VS 2031)
8.6.2 North America Human Erythropoietin Revenue by Country (2020-2025)
8.6.3 North America Human Erythropoietin Revenue by Country (2026-2031)
8.6.4 United States
8.6.5 Canada
9 Europe
9.1 Europe Human Erythropoietin Revenue (2020-2031)
9.2 Europe Human Erythropoietin Revenue by Type (2020-2031)
9.2.1 Europe Human Erythropoietin Revenue by Type (2020-2025)
9.2.2 Europe Human Erythropoietin Revenue by Type (2026-2031)
9.3 Europe Human Erythropoietin Revenue Share by Type (2020-2031)
9.4 Europe Human Erythropoietin Revenue by Application (2020-2031)
9.4.1 Europe Human Erythropoietin Revenue by Application (2020-2025)
9.4.2 Europe Human Erythropoietin Revenue by Application (2026-2031)
9.5 Europe Human Erythropoietin Revenue Share by Application (2020-2031)
9.6 Europe Human Erythropoietin Revenue by Country
9.6.1 Europe Human Erythropoietin Revenue by Country (2020 VS 2024 VS 2031)
9.6.2 Europe Human Erythropoietin Revenue by Country (2020-2025)
9.6.3 Europe Human Erythropoietin Revenue by Country (2026-2031)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Netherlands
10 China
10.1 China Human Erythropoietin Revenue (2020-2031)
10.2 China Human Erythropoietin Revenue by Type (2020-2031)
10.2.1 China Human Erythropoietin Revenue by Type (2020-2025)
10.2.2 China Human Erythropoietin Revenue by Type (2026-2031)
10.3 China Human Erythropoietin Revenue Share by Type (2020-2031)
10.4 China Human Erythropoietin Revenue by Application (2020-2031)
10.4.1 China Human Erythropoietin Revenue by Application (2020-2025)
10.4.2 China Human Erythropoietin Revenue by Application (2026-2031)
10.5 China Human Erythropoietin Revenue Share by Application (2020-2031)
11 Asia (Excluding China)
11.1 Asia Human Erythropoietin Revenue (2020-2031)
11.2 Asia Human Erythropoietin Revenue by Type (2020-2031)
11.2.1 Asia Human Erythropoietin Revenue by Type (2020-2025)
11.2.2 Asia Human Erythropoietin Revenue by Type (2026-2031)
11.3 Asia Human Erythropoietin Revenue Share by Type (2020-2031)
11.4 Asia Human Erythropoietin Revenue by Application (2020-2031)
11.4.1 Asia Human Erythropoietin Revenue by Application (2020-2025)
11.4.2 Asia Human Erythropoietin Revenue by Application (2026-2031)
11.5 Asia Human Erythropoietin Revenue Share by Application (2020-2031)
11.6 Asia Human Erythropoietin Revenue by Country
11.6.1 Asia Human Erythropoietin Revenue by Country (2020 VS 2024 VS 2031)
11.6.2 Asia Human Erythropoietin Revenue by Country (2020-2025)
11.6.3 Asia Human Erythropoietin Revenue by Country (2026-2031)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 Taiwan
11.6.9 Southeast Asia
12 South America, Middle East and Africa
12.1 SAMEA Human Erythropoietin Revenue (2020-2031)
12.2 SAMEA Human Erythropoietin Revenue by Type (2020-2031)
12.2.1 SAMEA Human Erythropoietin Revenue by Type (2020-2025)
12.2.2 SAMEA Human Erythropoietin Revenue by Type (2026-2031)
12.3 SAMEA Human Erythropoietin Revenue Share by Type (2020-2031)
12.4 SAMEA Human Erythropoietin Revenue by Application (2020-2031)
12.4.1 SAMEA Human Erythropoietin Revenue by Application (2020-2025)
12.4.2 SAMEA Human Erythropoietin Revenue by Application (2026-2031)
12.5 SAMEA Human Erythropoietin Revenue Share by Application (2020-2031)
12.6 SAMEA Human Erythropoietin Revenue by Country
12.6.1 SAMEA Human Erythropoietin Revenue by Country (2020 VS 2024 VS 2031)
12.6.2 SAMEA Human Erythropoietin Revenue by Country (2020-2025)
12.6.3 SAMEA Human Erythropoietin Revenue by Country (2026-2031)
12.6.4 Brazil
12.6.5 Argentina
12.6.6 Chile
12.6.7 Colombia
12.6.8 Peru
12.6.9 Saudi Arabia
12.6.10 Israel
12.6.11 UAE
12.6.12 Turkey
12.6.13 Iran
12.6.14 Egypt
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.